ALK and anaplastic large cell lymphoma: These free drug concentrations exceed the 10 ng/mL IC50 of crizotinib in ALCL cell lines, Karpas299 and SU-DHL-1 that express the NPM-ALK fusion protein [10], consistent with the high objective response rate to crizotinib in children with ALCL treated on the phase 1/2 trial even at doses below the MTD [6].